Introduction: Insulin autoantibodies (IAA) are key predictors of type 1 diabetes, particularly in young children. Micro-radiobinding assays (RBA) are the gold standard for IAA measurement but have limitations. We assessed whether a luciferase immunoprecipitation system (LIPS) assay improved diabetes risk assessment. Methods: To validate LIPS compared with RBA, samples from people with new-onset type 1 diabetes (n = 150) and first-degree relatives (FDRs) (n = 619), of whom 91 had developed diabetes during follow-up, were used. This cross-sectional observational data was analysed using the area under the receiver operator characteristic curve and cox-proportional hazard models. Results: In new-onset diabetes, RBA and LIPS showed 88% agreement in IAA status. Positive IAA LIPS was more common in 89 FDRs with high-moderate affinity IAA (61%) compared with 22 FDRs with low-affinity IAA (18%) (p < 0.001). In FDRs positive for multiple other islet autoantibodies, 20-year diabetes risk was 80% for those positive compared with 30% for those negative for IAA by LIPS (p = 0.013). IAA LIPS added to diabetes risk independently of status/level of IAA by RBA, other autoantibodies and sampling age (p < 0.001). Conclusion: The IAA LIPS low-blood-volume, high-throughput technique identifies more individuals with the highest risk of diabetes. The ability to identify high-affinity IAA makes LIPS an ideal method for future clinical trials and population screening strategies to predict the risk of diabetes.

Improved prediction of symptomatic type 1 diabetes using a luciferase-based assay to measure (pro)insulin autoantibodies / Wyatt, R.C., Brigatti, C., Grace, S.L., Williams, C.L., Marzinotto, I., Gillard, B.T., Bazzigaluppi, E., Shoemark, D., Chandler, M.A.M., Achenbach, P., Piemonti, L., Wilson, I., Aitken, R., Kelland, I., Megson, C., Ballav, C., Dutta, A., Russell-Taylor, M., Besser, R., Bursell, J., et al.. - In: DIABETIC MEDICINE. - ISSN 0742-3071. - 43:8(2026). [10.1111/dme.70277]

Improved prediction of symptomatic type 1 diabetes using a luciferase-based assay to measure (pro)insulin autoantibodies

Marzinotto I.;Piemonti L.;
2026-01-01

Abstract

Introduction: Insulin autoantibodies (IAA) are key predictors of type 1 diabetes, particularly in young children. Micro-radiobinding assays (RBA) are the gold standard for IAA measurement but have limitations. We assessed whether a luciferase immunoprecipitation system (LIPS) assay improved diabetes risk assessment. Methods: To validate LIPS compared with RBA, samples from people with new-onset type 1 diabetes (n = 150) and first-degree relatives (FDRs) (n = 619), of whom 91 had developed diabetes during follow-up, were used. This cross-sectional observational data was analysed using the area under the receiver operator characteristic curve and cox-proportional hazard models. Results: In new-onset diabetes, RBA and LIPS showed 88% agreement in IAA status. Positive IAA LIPS was more common in 89 FDRs with high-moderate affinity IAA (61%) compared with 22 FDRs with low-affinity IAA (18%) (p < 0.001). In FDRs positive for multiple other islet autoantibodies, 20-year diabetes risk was 80% for those positive compared with 30% for those negative for IAA by LIPS (p = 0.013). IAA LIPS added to diabetes risk independently of status/level of IAA by RBA, other autoantibodies and sampling age (p < 0.001). Conclusion: The IAA LIPS low-blood-volume, high-throughput technique identifies more individuals with the highest risk of diabetes. The ability to identify high-affinity IAA makes LIPS an ideal method for future clinical trials and population screening strategies to predict the risk of diabetes.
2026
Inglese
John Wiley and Sons Inc
43
8
Pubblicato
Esperti anonimi
Internazionale
Goal 3: Good health and well-being
antibody affinity
autoimmunity
diabetes mellitus
insulin antibodies
luciferase
predictive value of tests
type 1
Improved prediction of symptomatic type 1 diabetes using a luciferase-based assay to measure (pro)insulin autoantibodies / Wyatt, R.C., Brigatti, C., Grace, S.L., Williams, C.L., Marzinotto, I., Gillard, B.T., Bazzigaluppi, E., Shoemark, D., Chandler, M.A.M., Achenbach, P., Piemonti, L., Wilson, I., Aitken, R., Kelland, I., Megson, C., Ballav, C., Dutta, A., Russell-Taylor, M., Besser, R., Bursell, J., et al.. - In: DIABETIC MEDICINE. - ISSN 0742-3071. - 43:8(2026). [10.1111/dme.70277]
none
37
info:eu-repo/semantics/article
262
Wyatt, R. C.; Brigatti, C.; Grace, S. L.; Williams, C. L.; Marzinotto, I.; Gillard, B. T.; Bazzigaluppi, E.; Shoemark, D.; Chandler, M. A. M.; Achenba...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/206919
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact